Kyle Doherty

Patients with mismatch repair–deficient and/or microsatellite instability metastatic colorectal cancer experienced a progression-free survival benefit with longer disease control following treatment with avelumab compared with standard second-line chemotherapy.

The combination of vemurafenib and cobimetinib led to a 94% partial response rate or better in 16 patients with newly diagnosed BRAF-mutated papillary craniopharyngiomas.

Treatment with the GVAX pancreatic cancer vaccine plus nivolumab and urelumab increased the presence of intratumoral activated cytotoxic T cells and showed early signs of efficacy in patients with resectable pancreatic adenocarcinoma.

Kedar Kirtane, MD, speaks on the unique mechanism of action of A2B530 and how the agent could represent a huge leap forward in the application of CAR T-cell agents for patients with solid tumors if the EVEREST-1 study proves to be positive.

The PD-1 inhibitor pembrolizumab displayed activity with a manageable safety profile in patients with certain rare and ultra-raresarcoma histotypes.

Treatment with intermittent or continuous doses of relacorilant in combination with nab-paclitaxel resulted in an overall survival benefit compared with nab-paclitaxel monotherapy, but failed to demonstrate an improvement in progression-free survival in patients with recurrent, platinum-resistant ovarian cancer.

Pembrolizumab produced sustained antitumor activity in patients with relapsed/refractory primary mediastinal large B-cell lymphoma, according to data from the final analysis of the phase 2 KEYNOTE-170 trial.

The addition of the type 1 FLT3 inhibitor gilteritinib to induction and consolidation chemotherapy, followed by maintenance gilteritinib monotherapy, was safe and tolerable with promising initial efficacy in patients with newly diagnosed acute myeloid leukemia.

Delays in time to treatment initiation may be associated with demographic and socioeconomic disparities, with care coordination, clinical, and socioeconomic factors representing potential predictors of TTI, according to findings from a retrospective cohort study published in JCO Oncology Practice.

Patients with low-grade upper tract urothelial carcinoma experienced similar rendered disease free rates, regardless of surgery type or tumor volume, following treatment with mitomycin for pyelocalyceal solution.

The implementation of a pharmacist-driven biosimilar substitution program across American Oncology Network institutions resulted in increased uptake of biosimilar agents as well as financial savings for payers, patients, and providers.

Varied levels of compliance were observed in terms of using validated quality indicators to determine the quality of active surveillance for patients with low-risk prostate cancer, according to findings from a population-based study published in the Journal of the Comprehensive Cancer Network.

Locoregional recurrence rates among patients with favorable-risk, node-positive hormone receptor-positive, HER2-negative breast cancer was not significantly reduced by the addition of regional nodal irradiation to these patient’s treatment regimens.

Neeraj Agarwal, MD, speaks on the significance of the approval and how the combination of talazoparib and enzalutamide will fit into the treatment landscape of HRR gene–mutated mCRPC.

The third-generation EGFR TKI lazertinib displayed a significant efficacy improvement compared with gefitinib in patients with EGFR-mutated advanced non–small cell lung cancer when given in the first-line.

The DecisionDx-Melanoma 31-gene expression profile test displayed the capability to stratify patients with cutaneous melanoma by risk of death from the disease and receival of the 31-GEP test may result in a survival benefit compared with untested patients.

Although the use of immunotherapy treatment approaches continues to become more prevalent in advanced renal cell carcinoma, high-level evidence showing benefit of sequential administration of these agents are limited.

As antibody-drug conjugates become an established part of the lung cancer treatment paradigm, identifying which patients will benefit the most from treatment with these highly specific agents remains a challenge for clinicians.

Efforts to develop the first FDA-approved agent specifically for patients with primary central nervous system lymphoma have been initiated with the phase 2 PROSPECT trial.

Yasushi Goto, MD, PhD, delves into the details of the TROPION-Lung02 trial.

Leading investigators in the multiple myeloma field discuss the latest clinical trial findings, many of which were presented during the 2023 ASCO Annual Meeting.

Treatment with trastuzumab deruxtecan resulted in clinically meaningful efficacy in patients with HER2-positive gastric or gastroesophageal junction cancer following disease progression on or after a trastuzumab-containing regimen.

The addition of lutetium Lu 177 vipivotide tetraxetan to standard-of-care treatment delayed time to worsening of health-related quality of life and skeletal events compared with standard of care alone for patients with metastatic castration-resistant prostate cancer.

John O. Mascarenhas, MD, discusses the design and rationale of the KRT-232-109 trial, key findings from the trial, and potential future directions of the study.

The National Comprehensive Cancer Network has announced a guideline update concerning the treatment of patients with acute lymphoblastic leukemia, B-cell lymphomas, pediatric ALL, and pediatric aggressive mature B-cell lymphoma.

Adagrasib has demonstrated intracranial activity among patients with KRAS G12C–mutated non–small cell lung cancer with untreated central nervous system metastases.

Investigators of the phase 1/2 KOMET-001 trial are seeking to address unmet needs in AML with the investigational menin inhibitor ziftomenib.

Patients with intermediate-2 or high-risk myelofibrosis who received the novel JAK/ACVR1 inhibitor jaktinib experienced a statistically significant improvement in the proportion of patients with a spleen-volume reduction of at least 35% from baseline at week 24 vs those who were treated with hydroxyurea.

Looking to replicate the impressive findings with CAR T-cell therapies observed in patients with hematologic malignancies, investigators have initiated the BASECAMP-1 trial with the hope of identifying patients with advanced solid tumors who will be suitable candidates for treatment in the EVEREST trial.

Fam-trastuzumab deruxtecan-nxki demonstrated clinically meaningful activity across a wide range of HER2 expressing solid tumors, including hard-to-treat tumors, according to findings from the phase 2 DESTINY-PanTumor02 trial.